Results 181 to 190 of about 18,729 (264)

Management of hypertension in chronic kidney disease. [PDF]

Clin Med (Lond)
Doulton T, Swift PA, Hiremath S.
europepmc   +1 more source

Long term safety and efficacy of a functionalized nanogel with endothelin-1 and bradykinin receptor antagonist peptides for treatment of osteoarthritis of the metacarpophalangeal and distal interphalangeal joints in horses: a descriptive clinical pilot study. [PDF]

BMC Vet Res
Terlinden A, Jacquet S, Manivong S, Coudry V, Tallaj A, Cullier A, Legendre F, Garcia AA, Moldovan F, Sirois P, Banquy X, Galéra P, Audigié F, Roullin G, Demoor M, Bertoni L.   +15 more
europepmc   +1 more source

Obstructive sleep apnoea and hypertension: Current understanding, diagnosis and management. [PDF]

Clin Med (Lond)
Afzal M, Livesey A, Hameed MA, Mukherjee R.   +3 more
europepmc   +1 more source

An Explorative Approach to Examining the Role of Ischemia and Inflammation on the Function of Autoantibodies Against G Protein-Coupled Receptors and Their Corresponding Agonists. [PDF]

Int J Mol Sci
Wallukat G, Lakatos P, Steinhorst K, Flecks M, Hohberger B.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Endothelin Receptor Antagonist

2017
Endothelin (ET)-1, a peptide mainly produced by vascular endothelial cells, has potent and long-lasting vasoconstrictive effect. In addition, ET-1 has been shown to induce a variety of biological effects including cell proliferation, inflammation, and fibrosis.
N. Emoto
openaire   +2 more sources

Endothelin Receptor Antagonists [PDF]

Pharmacology & Therapeutics, 2006
Endothelin receptor antagonists (ERAs) have been developed to block the effects of endothelin-1 (ET-1) in a variety of cardiovascular conditions. ET-1 is a powerful vasoconstrictor with mitogenic or co-mitogenic properties, which acts through the stimulation of 2 subtypes of receptors [endothelin receptor subtype A (ETA) and endothelin receptor subtype
J D, Elliott, E H, Ohlstein, C E, Peishoff, H M, Ellens, M A, Lago   +4 more
  +6 more sources

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study

Lancet, The, 2001
Richard N Channick, Gerald Simonneau, Olivier Sitbon   +2 more
exaly   +2 more sources

Aprocitentan (a Dual Endothelin-Receptor Antagonist) for Treatment-Resistant Hypertension

Journal of Cardiovascular Pharmacology, 2021
: Treatment-resistant hypertension (TRH) is associated with increased cardiovascular risks and progression of chronic kidney disease. The pathophysiology of TRH is multifactorial, including overactivity of the renin–angiotensin–aldosterone system and ...
Emily K. McCoy, Katelin M. Lisenby
semanticscholar   +1 more source

Endothelin receptor antagonists

World Journal of Urology, 2005
Hormone refractory prostate cancer remains true to its middle name: it is largely refractory to attempts to delay its progression. New targets and new therapies are demanded. Through a review of the available literature on endothelin and several preclinical observations, the endothelin axis has emerged as one such target.
Michael, Kirchengast, Matthias, Luz
openaire   +4 more sources

The endothelin system and endothelin receptor antagonists

Current Opinion in Nephrology & Hypertension, 2012
There is increasing evidence that endothelin receptor blockade and, in particular, ET(A) receptor blockade not only confers protection against proteinuric renal disease in diabetes but also confers vasculoprotection.Recent clinical trials using ET(A) receptor blockade in treating proteinuria and chronic kidney disease as well as atherosclerosis show ...
Karin A M, Jandeleit-Dahm, Anna M D, Watson   +1 more
openaire   +2 more sources